STAT

They had power and status on the East Coast. So why did these health care gurus decamp for California? To change the world

What happens when top doctors and scientists leave the power hubs of the East Coast for Silicon Valley? Here, their unvarnished views of California.

PALO ALTO, Calif. — It’s easy to think, from the headlines, that the future of health care is being forged on Capitol Hill. But the traditional centers of power and influence are losing ground — and talent — to the fertile, sometimes chaotic, environs of Silicon Valley.

What happens when top biomedical scientists and health policy experts head west? What do they find in California? And what lessons do they draw?

To find out, STAT invited five leading voices in California’s health care startup culture to a roundtable discussion at the offices of Mindstrong Health, a startup seeking to use data gathered from smartphones to diagnose and treat mental illness. A sixth interview, with Dr. Atul Butte, was conducted earlier in San Francisco.

Here are the lessons these scientists and entrepreneurs draw from their cross-country migration. And one editorial note: We’d love to hear responses from East Coast denizens working on health care innovation from Kendall Square, Research Triangle, D.C., or elsewhere. Please use the comment box at the end of the article to share

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Lilly Buying A Plant, A Pfizer Antibiotic, And More
Eli Lilly agreed to acquire a manufacturing facility in Wisconsin from Nexus Pharmaceuticals to produce injectable medicines amid shortages of Mounjaro and Zepbound.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About An OptumRx Contract, 340B Dispute Resolution, And More
Cardinal Health announced its pharmaceutical distribution contracts with UnitedHealth's OptumRx unit will not be renewed after they expire in June.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About CVS And Humira Biosimilars, Schumer’s Broken Insulin Promise, And More
New prescriptions for biosimilar versions of Humira, one of the best-selling drugs in the U.S., surged to 36% from just 5% during the first week of April.

Related Books & Audiobooks